Market Overview
Global Medical Sodium Hyaluronate Injection market size was valued at USD 1.78 billion in 2024. The market is projected to grow from USD 1.85 billion in 2025 to USD 2.31 billion by 2031, exhibiting a CAGR of 3.9% during the forecast period.
Medical Sodium Hyaluronate Injection, also known as viscosupplementation, is a therapeutic procedure involving the injection of hyaluronic acid-based solutions into joints. Primarily used to treat osteoarthritis symptoms, particularly in knee joints, these injections act as lubricants and shock absorbers to improve mobility and reduce pain. The treatment is classified into single, three, and five injection regimens based on dosage requirements.
USD 1.78 billion in 2024
2032 USD 2.31 billion by 2031
of 3.9%
Single Injection Segment Dominates the Market Due to Enhanced Patient Convenience and Reduced
Treatment Burden
The market is segmented based on type into:
Single Injection
Three Injection
Five Injection
The single injection type leads owing to its simplicity, allowing patients to complete treatment in one visit, which minimizes discomfort and improves adherence compared to multi-dose regimens. This segment benefits from technological advancements in hyaluronic acid cross-linking, enabling longer-lasting effects. Three and five injection types remain relevant for patients requiring gradual dosing, particularly in cases of moderate osteoarthritis, but they hold smaller shares due to logistical challenges in outpatient settings.
By Application
The market is segmented based on application into: Hospitals
Clinics
Others Hospitals dominate as primary sites for viscosupplementation procedures, supported by specialized orthopedic departments and access to imaging diagnostics. This segment accounts for the majority of injections administered, driven by the need for comprehensive patient care in complex cases. Clinics are gaining traction for routine treatments, offering cost-effective alternatives, while the 'others' category includes ambulatory surgical centers and rehabilitation facilities, where demand is growing with the push for outpatient care.
Portable Neuromonitoring Device Market
Our Key Players
Sanofi (France)
Anika Therapeutics, Inc. (U.S.)
Seikagaku Corporation (Japan)
Zimmer Biomet Holdings, Inc. (U.S.)
Bioventus LLC (U.S.)
Ferring Pharmaceuticals (Switzerland)
https://www.24lifesciences.com
